[go: up one dir, main page]

NO20055838L - Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav - Google Patents

Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav

Info

Publication number
NO20055838L
NO20055838L NO20055838A NO20055838A NO20055838L NO 20055838 L NO20055838 L NO 20055838L NO 20055838 A NO20055838 A NO 20055838A NO 20055838 A NO20055838 A NO 20055838A NO 20055838 L NO20055838 L NO 20055838L
Authority
NO
Norway
Prior art keywords
binding protein
medical applications
active variants
active fragments
active
Prior art date
Application number
NO20055838A
Other languages
English (en)
Other versions
NO20055838D0 (no
NO338682B1 (no
Inventor
Valter Altarocca
Anna R Pezzotti
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20055838D0 publication Critical patent/NO20055838D0/no
Publication of NO20055838L publication Critical patent/NO20055838L/no
Publication of NO338682B1 publication Critical patent/NO338682B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Det beskrives aktive fragmenter av det IL-18 bindende protein, farmasøytiske preparater inneholdende slike aktive fragmenter samt den medisinske anvendelse derav.
NO20055838A 2003-05-13 2005-12-08 IL-18 bindingsprotein (IL-18BP), en sammensetning, fremgangsmåte for fremstilling samt anvendelse NO338682B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101326 2003-05-13
PCT/EP2004/005073 WO2004101617A1 (en) 2003-05-13 2004-05-11 Active variants of the il-18 binding protein and medical uses thereof

Publications (3)

Publication Number Publication Date
NO20055838D0 NO20055838D0 (no) 2005-12-08
NO20055838L true NO20055838L (no) 2006-02-13
NO338682B1 NO338682B1 (no) 2016-09-26

Family

ID=33442815

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055838A NO338682B1 (no) 2003-05-13 2005-12-08 IL-18 bindingsprotein (IL-18BP), en sammensetning, fremgangsmåte for fremstilling samt anvendelse

Country Status (16)

Country Link
US (2) US20080076708A1 (no)
EP (1) EP1622939B1 (no)
JP (1) JP5074030B2 (no)
AT (1) ATE549353T1 (no)
AU (1) AU2004238524B2 (no)
CA (1) CA2524403C (no)
CY (1) CY1112682T1 (no)
DK (1) DK1622939T3 (no)
ES (1) ES2384241T3 (no)
HR (1) HRP20120246T1 (no)
IL (1) IL171914A (no)
NO (1) NO338682B1 (no)
PL (1) PL1622939T3 (no)
PT (1) PT1622939E (no)
SI (1) SI1622939T1 (no)
WO (1) WO2004101617A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332579A3 (en) * 2000-02-10 2011-09-21 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
CA2516157C (en) * 2003-03-11 2012-09-18 Applied Research Systems Ars Holding N.V. Expression vectors comprising the mcmv ie2 promoter
EP1675956B1 (en) * 2003-10-21 2010-10-13 Merck Serono SA Minimal dna sequence acting as a chromatin insulator and its use in protein expression
ES2285543T3 (es) 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP1720979B1 (en) * 2004-03-01 2007-10-10 Ares Trading S.A. Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
WO2006003134A1 (en) 2004-06-29 2006-01-12 Ares Trading S.A. Process for the purification of il-18 binding protein
SI2267024T1 (sl) * 2005-06-03 2012-09-28 Ares Trading Sa Proizvodnja rekombinantnega IL-18 vezavnega proteina
PL1888100T3 (pl) 2005-06-03 2012-03-30 Merck Serono Sa Zastosowanie lizoform IL-18BP do leczenia i/lub zapobiegania neurologicznym chorobom zapalnym
RS52273B (sr) 2005-06-10 2012-10-31 Ares Trading S.A. Proces za purifikaciju il-18 vezujućeg proteina
CN103228290A (zh) * 2011-02-18 2013-07-31 (株)斯坦帝尔 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
KR102512797B1 (ko) 2013-09-05 2023-03-22 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
EP3265807A1 (en) 2015-03-05 2018-01-10 AB2 Bio SA Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
IL305370A (en) * 2017-09-06 2023-10-01 Univ Yale Variants of interleukin-18 and methods of use
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
JP4216950B2 (ja) * 1998-09-01 2009-01-28 株式会社林原生物化学研究所 インターロイキン−１８結合蛋白質
CA2407895C (en) 2000-05-05 2012-12-18 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
ES2295332T3 (es) 2001-01-29 2008-04-16 Laboratoires Serono Sa Uso de inhibidores de il-18 para el tratamiento y/o prevencion de cardiopatias.
CN100556450C (zh) 2001-05-16 2009-11-04 耶达研究发展有限公司 Il-18抑制剂在治疗或预防脓毒症中的应用
US7655616B2 (en) 2001-05-25 2010-02-02 Ares Trading S.A. Use of IL-18 inhibitors for treating head injuries
JP2005505608A (ja) 2001-10-11 2005-02-24 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 糖尿病性神経障害でのｇｐ１３０アクチベーターの使用法
CA2516157C (en) * 2003-03-11 2012-09-18 Applied Research Systems Ars Holding N.V. Expression vectors comprising the mcmv ie2 promoter
EP1675956B1 (en) * 2003-10-21 2010-10-13 Merck Serono SA Minimal dna sequence acting as a chromatin insulator and its use in protein expression
ES2285543T3 (es) * 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
EP1720979B1 (en) * 2004-03-01 2007-10-10 Ares Trading S.A. Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
WO2006003134A1 (en) * 2004-06-29 2006-01-12 Ares Trading S.A. Process for the purification of il-18 binding protein
SI2267024T1 (sl) * 2005-06-03 2012-09-28 Ares Trading Sa Proizvodnja rekombinantnega IL-18 vezavnega proteina
RS52273B (sr) * 2005-06-10 2012-10-31 Ares Trading S.A. Proces za purifikaciju il-18 vezujućeg proteina

Also Published As

Publication number Publication date
WO2004101617A1 (en) 2004-11-25
EP1622939B1 (en) 2012-03-14
IL171914A0 (en) 2006-04-10
HRP20120246T1 (hr) 2012-04-30
CA2524403A1 (en) 2004-11-25
DK1622939T3 (da) 2012-04-10
EP1622939A1 (en) 2006-02-08
JP5074030B2 (ja) 2012-11-14
SI1622939T1 (sl) 2012-06-29
NO20055838D0 (no) 2005-12-08
ES2384241T3 (es) 2012-07-02
US20110189131A1 (en) 2011-08-04
AU2004238524B2 (en) 2011-06-23
NO338682B1 (no) 2016-09-26
PL1622939T3 (pl) 2012-08-31
PT1622939E (pt) 2012-03-28
CY1112682T1 (el) 2016-02-10
CA2524403C (en) 2013-07-09
ATE549353T1 (de) 2012-03-15
IL171914A (en) 2013-05-30
JP2007535903A (ja) 2007-12-13
AU2004238524A1 (en) 2004-11-25
US20080076708A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
PL371736A1 (en) Method for administering glp-1 molecules
NO20062508L (no) Administrering av levodopa og karbidopa
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE602004020901D1 (de) System zur Einführung von mehreren Medizinprodukten
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
IS2842B (is) Salt perindópríls og lyfjablöndur sem innihalda það. Lyf.
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
DK1404304T3 (da) Tablet omfattende cetirizin og pseudoephedrin
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
NO20050066L (no) Pegylert T20 polypeptid
NO20051983D0 (no) 3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
EP1663201A4 (en) USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
NO20042890L (no) Farmasoytiske preparater og fremgangsmate for fremstilling derav
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO